Local Burden of Disease Diarrhoea Collaborators, & Adekanmbi, V. (2020). Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000-17. *The Lancet. Global health*, 8(8), e1038-e1060. https://doi.org/10.1016/S2214-109X(20)30230-8
Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17

Local Burden of Disease Diarrhoea Collaborators*

Summary

Background Oral rehydration solution (ORS) is a form of oral rehydration therapy (ORT) for diarrhoea that has the potential to drastically reduce child mortality; yet, according to UNICEF estimates, less than half of children younger than 5 years with diarrhoea in low-income and middle-income countries (LMICs) received ORS in 2016. A variety of recommended home fluids (RHF) exist as alternative forms of ORT; however, it is unclear whether RHF prevent child mortality. Previous studies have shown considerable variation between countries in ORS and RHF use, but subnational variation is unknown. This study aims to produce high-resolution geospatial estimates of relative and absolute coverage of ORS, RHF, and ORT (use of either ORS or RHF) in LMICs.

Methods We used a Bayesian geostatistical model including 15 spatial covariates and data from 385 household surveys across 94 LMICs to estimate annual proportions of children younger than 5 years of age with diarrhoea who received ORS or RHF (or both) on continuous continent-wide surfaces in 2000–17, and aggregated results to policy-relevant administrative units. Additionally, we analysed geographical inequality in coverage across administrative units and estimated the number of diarrhoeal deaths averted by increased coverage over the study period. Uncertainty in the mean coverage estimates was calculated by taking 250 draws from the posterior joint distribution of the model and creating uncertainty intervals (UIs) with the 2.5th and 97.5th percentiles of those 250 draws.

Findings While ORS use among children with diarrhoea increased in some countries from 2000 to 2017, coverage remained below 50% in the majority (62.6%; 12,417 of 19,823) of second administrative-level units and an estimated 6,519,000 children (95% UI 5,254,000–7,733,000) with diarrhoea were not treated with any form of ORT in 2017. Increases in ORS use corresponded with declines in RHF in many locations, resulting in relatively constant overall ORT coverage from 2000 to 2017. Although ORS was uniformly distributed subnationally in some countries, within-country geographical inequalities persisted in others; 11 countries had at least a 50% difference in one of their units compared with the country mean. Increases in ORS use over time were correlated with declines in RHF use and in diarrhoeal mortality in many locations, and an estimated 52,230 diarrhoeal deaths (36,910–68,860) were averted by scaling up of ORS coverage between 2000 and 2017. Finally, we identified key subnational areas in Colombia, Nigeria, and Sudan as examples of where diarrhoeal mortality remains higher than average, while ORS coverage remains lower than average.

Interpretation To our knowledge, this study is the first to produce and map subnational estimates of ORS, RHF, and ORT coverage and attributable child diarrhoeal deaths across LMICs from 2000 to 2017, allowing for tracking progress over time. Our novel results, combined with detailed subnational estimates of diarrhoeal morbidity and mortality, can support subnational needs assessments aimed at furthering policy makers’ understanding of within-country disparities. Over 50 years after the discovery that led to this simple, cheap, and life-saving therapy, large gains in reducing mortality could still be made by reducing geographical inequalities in ORS coverage.

Funding Bill & Melinda Gates Foundation.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction Oral rehydration solution (ORS) is a simple treatment that can be prepared and used at home to prevent mortality due to dehydration and undernutrition in children with diarrhoea. This intervention is especially suitable in locations where intravenous fluids are scarce or unavailable, and replaces indiscriminate and unnecessary use of antibiotics to treat diarrhoea. ORS was discovered more than 50 years ago when a physician in Dhaka, Bangladesh, found that treating patients with cholera with glucose-electrolyte solutions in equivalent amounts to fluid losses could prevent the need for intravenous liquids in 80% of patients. Shortly thereafter, its ability to prevent dehydration was shown in a trial in Kolkata, India, and during a cholera outbreak among Bangladeshi refugees in India. Since then,
WHO, UNICEF, and the US Centers for Disease Control and Prevention have promoted ORS as an essential medicine to treat diarrhoea, the third leading cause of death in children younger than 5 years of age worldwide.\(^4\) In the 1980s, in response to low ORS coverage (ie, the proportion of children with diarrhoea who received ORS), WHO promoted the use of so-called recommended home fluids (RHF) in addition to ORS, and oral rehydration therapy (ORT) became the phrase used to home fluids (RHF) in low-income and middle-income countries (LMICs) in 2000 received ORS to treat diarrhoea; in 2016, the proportion increased to 44%, yet the majority remained untreated.\(^4\) The efficacy of ORS and RHF in preventing child mortality relies on proper preparation of the solutions, which can vary depending on the resources available to a household. ORS is most commonly sold as premade packets with standardised sodium and glucose content, which need to be dissolved in 1 L of clean water and can then be stored for about 48 h.\(^1\) The cost of these packets varies by country; in Uganda, a single packet costs approximately 500 Ugandan shillings (about US$0·15),\(^1\) and in Nigeria in 2012, the cost of three packets ranged from $0·63 to $4·38 depending on location.\(^9\) By contrast, RHF can be made with household items and therefore can be less costly and more widely accessible. The composition of RHF varies by country and can include carefully measured sugar and salt added to clean water, or it can simply include plain juice, rice water, tea, or coconut water.\(^1\) A meta-analysis study in 2010 estimated that 100% coverage of ORS could prevent 230 deaths (36 910–68 860) across LMICs in 2017. Despite progress, coverage of ORS (ie, the proportion of children with diarrhoea who received ORS) remained below 50% in many locations where diarrhoea prevalence and mortality rates remain high. Importantly, we also show that while within-country geographical inequalities declined over time, large disparities remained in multiple countries with high diarrhoeal burden, including subnational areas of Colombia, Peru, Nigeria, and Sudan.

Evidence before this study
WHO’s integrated Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea emphasises the need to make resources available to properly prevent and treat these childhood infections, including use of oral rehydration solution (ORS) to treat diarrhoea. In 2016, UNICEF published national-level estimates of the proportion of children with diarrhoea who received ORS or any alternative recommended home fluids (RHF) for countries and years with available household survey data. To understand the full landscape of currently published estimates, we did a literature review on Feb 11, 2019, with no date or language restrictions. We searched the PubMed database for the following terms in titles or abstracts: “ORS”, “ORT”, “RHF”, “oral rehydration solution”, “oral rehydration therapy”, “oral rehydration salts”, and “recommended home fluids”, with the necessary inclusion of “coverage”. This returned 229 total studies, seven of which presented or reviewed national-level estimates of ORS coverage globally or across multiple countries, and 26 of which estimated ORS or RHF subnational coverage in select countries. None of these studies, however, estimated ORS or RHF coverage subnationally across multiple regions or used geospatial modelling techniques to estimate ORS or RHF coverage in locations with sparse data.

Added value of this study
To our knowledge, this study presents the first high-resolution subnational estimates of the proportion and absolute number of children younger than 5 years with diarrhoea that received ORS or RHF in low-income and middle-income countries (LMICs) from 2000 to 2017. This work supports the examination of how patterns of coverage have changed over time since the establishment of the Millennium Development Goals in 2000, the identification of subnational areas in need of targeted interventions, and the stratification of oral rehydration therapy coverage into ORS and RHF estimates. We used Bayesian geostatistical modelling techniques and an extensive geolocated dataset to produce these estimates. Wherever possible, we tailored these methods to take into account national or subnational factors that might contribute to variation in ORS coverage, using spatially resolved covariates to estimate for areas with sparse data. These techniques produced estimates on continuous continent-wide surfaces, which we aggregated to policy-relevant administrative units. We show that ORS use has increased over time, and that increases in ORS use often corresponded to declines in RHF use to treat diarrhoea and in diarrhoeal mortality rate. We estimate that scaling up of ORS treatment over the study period prevented an estimated 52 230 deaths (36 910–68 860) across LMICs in 2017. Despite progress, coverage of ORS (ie, the proportion of children with diarrhoea who received ORS) remained below 50% in many locations where diarrhoea prevalence and mortality rates remain high. Importantly, we also show that while within-country geographical inequalities declined over time, large disparities remained in multiple countries with high diarrhoeal burden, including subnational areas of Colombia, Peru, Nigeria, and Sudan.

Implications of all the available evidence
Our mapped estimates identify areas with low ORS usage, which could indicate gaps in access to ORS or knowledge of its efficacy to treat diarrhoea, and illuminate areas where improvements in ORS coverage are needed. Together with maps of other key risk factors, including sanitation and childhood stunting, these results can be used to develop integrated strategies that prevent diarrhoeal morbidity and mortality on a local level. These estimates and corresponding visualisation tools can aid policy makers and public health practitioners in determining where increased efforts to reduce geographical inequalities in ORS coverage are needed to make further strides in reducing mortality with this simple therapy.
93% of diarrhoeal deaths, yet found insufficient evidence on the effectiveness of RHF in preventing mortality, probably due to the broad range in RHF composition.16

To understand trends in diarrhoeal deaths and ORT coverage across space and time, it is crucial to analyse ORS and RHF treatment separately. A study in Ethiopia found subnational geographical variation in ORT coverage, which was driven primarily by differences in wealth.19 A recent study including data from 88 LMICs showed an 8 percentage-point difference in ORT coverage on average between the wealthiest and poorest household quintiles, which was low compared with other interventions such as improvements to water and sanitation.20 These studies, however, did not analyse ORS and RHF separately and might have underestimated variation. Other studies have shown that ORS use can vary broadly between countries, even between those sharing borders.11,17 Additionally, studies have shown differences in ORS use between urban and rural populations in Kenya18 and Mexico.19 These findings suggest that there are subnational drivers of variation in ORS coverage, and that these drivers can differ between geographical regions. Moreover, previous studies showed subnational variation in diarrhoeal deaths and overall deaths in children younger than 5 years,20–22 some of which might be driven by subnational variation in ORS given its efficacy in reducing child mortality.

Furthermore, policies related to diarrhoea treatment set at the national level do not affect all subnational areas equally, and interventions are often implemented at the subnational level, such as those currently done in Nigeria and India.23,24 Local-level estimates of ORS and RHF coverage are thus needed to identify vulnerable subpopulations most in need of increased efforts to prevent child mortality. Yet, to our knowledge, no study has estimated ORS coverage subnationally across multiple regions or has used geospatial modelling techniques to estimate ORS coverage in locations with sparse data, and no study has compared ORS coverage to patterns in RHF coverage.

Our aim in this study was to estimate the proportions of children with diarrhoea who were treated with ORS and RHF (ie, ORS and RHF coverage, respectively) over space and time in LMICs and examine geographical inequalities within countries. Here we present, to our knowledge, the first maps of ORS or RHF coverage for second administrative-level units (eg, districts, counties; henceforth referred to as units) in LMICs. We present both relative quantities (proportion of children) and absolute quantities (number of children), as these measures have distinct policy implications. We conclude by highlighting countries with some of the broadest differences in coverage across subnational units, which also have high diarrhoeal burdens and high subnational variation in mortality.

**Methods**

**Definitions**

For this study, ORS was defined as a pre-packaged electrolyte solution containing glucose or another form of sugar or starch, as well as sodium, chloride, potassium, and bicarbonate.18 Survey questions did not allow us to separate RHF into their different formulations; therefore, RHF were defined as all possible home fluid alternatives, including sugar-salt solution, cereal-salt solution, rice-water solution, and additional fluids, such as plain water, juice, tea, or rice water.18 To account for this variation, we adjusted all non-standard RHF definitions to the most common or standard definition across all surveys, using logistic regression to determine adjustments (appendix 1 p 3). ORT was defined as treatment with either ORS, RHF, or both. Coverage was defined as the proportion of children younger than 5 years of age with diarrhoea who received ORS, RHF, or ORT. Diarrhoea was defined as three or more abnormally loose or watery stools within a 24-h period.

**Data**

We compiled 385 household surveys (including Demographic and Health Surveys, Multiple Indicator Cluster Surveys, and other country-specific surveys) representing 3609000 children with diarrhoea in 94 LMICs from 2000 to 2017, with geocoded information from 120742 coordinates corresponding to survey clusters and 14055 subnational polygon boundaries where point-level referencing was not available (appendix 1 p 4). We included surveys that asked if children younger than 5 years with diarrhoea received any kind of ORT, allowed for geolocation below the country level, and were representative of the populations in which they were conducted. We included surveys for countries classified as low income or middle income on the basis of their Socio-demographic Index (SDI) quintile: low SDI, low-middle SDI, or middle SDI.25 SDI, developed as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), indicates the level of development based on a country’s average education, fertility, and income, and is on a scale of 0 to 1.25 Only LMICs with relevant and available underlying data were included in subsequent analyses, and island nations with fewer than 1 million inhabitants were excluded (appendix 1 p 4). This study complied with the Guidelines for Accurate and Transparent Health Estimates Reporting recommendations (appendix 1 pp 85–86).26 Further details on data inclusion, coverage, and validation can be found in appendix 1 (pp 4, 8).

We compiled 15 spatial covariates that were indexed at the subnational level for all 94 countries included in the study and that had conceivable relationships with ORT, which were used as predictors in our model. Covariates related to urbanicity or access to cities were night-time lights, population, urban or rural location, urban proportion of the location, and access to cities. Covariates related to child health, support, and nutrition were...
prevalence of under-5 stunting, prevalence of under-5 wasting, ratio of child dependents (ages 0–14 years) to working adults (ages 15–64 years), number of children younger than 5 years per woman of childbearing age, number of people whose daily vitamin A needs could be met, and maternal education. Covariates related to environmental factors that might affect diarrhoeal burden, which might in turn affect ORS supply, were aridity, distance from rivers or lakes, elevation, and irrigation. We also included the Healthcare Access and Quality Index and the proportion of pregnant women who received four or more antenatal care visits as national-level covariates. We filtered these covariates for multicollinearity within each modelling region (appendix 1 p 5) using variance inflation factor (VIF) analysis with a VIF threshold of 3. Detailed covariate information can be found in appendix 1 (p 5).

**Statistical analysis**

Analyses were done using R version 3.5.0. ORS, RHF, and ORT coverage were modelled separately using a Bayesian model-based geostatistical framework. Briefly, this framework uses a spatially and temporally explicit hierarchical logistic regression model to predict coverage in all locations, assuming that points that are closer together in space and time and that have similar covariate patterns have similar coverage. Potential non-linear relationships between covariates and coverage were incorporated through the use of a stacked generalisation technique. Posterior distributions of all model parameters and hyperparameters were estimated using the statistical package R-INLA (version 19.05.30.9000). Uncertainty in the mean coverage estimates was calculated by taking 250 draws from the posterior joint distribution of the model, and each point value is reported with an uncertainty interval (UI), which represents the 2.5th and 97.5th percentiles of those 250 draws. Maps were produced using ArcGIS Desktop 10.6. Models were run independently in 14 geographically distinct modelling regions based on GBD, and an additional nine country-specific models due to distinct temporal patterns of ORS coverage in these countries compared with their surrounding regions. Additional methodological details can be found in appendix 1 (pp 5–7).

Models were validated using five-fold cross-validation. Holdout sets were created by combining randomised sets of datapoints at the second administrative-unit cluster level. Model performance was summarised by the bias (mean error), total variance (root-mean-square error), and 95% data coverage within prediction intervals, and correlation between observed data and predictions. Where possible, estimates from these models were compared against other existing estimates. All validation procedures and corresponding results are provided in appendix 1 (p 8).

We calculated population-weighted aggregations of the 250 draws of ORS, RHF, and ORT coverage estimates at the country level, first administrative-level unit, and second administrative-level unit. To quantify geographical inequalities within countries over time, we used three different measures of inequality, each with their own strengths. We calculated Gini coefficients as a summary measure of inequality at the country level; in brief, the Gini coefficient summarises the distribution of each indicator across the population, with a value of 0 representing perfect equality and a value of 1 representing maximum inequality (appendix 1 p 9). We quantified absolute percentage-point deviation from the country mean to illustrate the total percentage-point difference in coverage between each unit and its country mean. Finally, we used relative deviation from the country mean to illustrate the difference in ORS coverage between each unit and its country mean.

To investigate the relationship between ORT and diarrhoeal mortality, we used mortality estimates from Reiner and colleagues and compared them with ORS coverage at the country and second administrative-unit levels. In addition, we did a counterfactual analysis to determine the estimated number of deaths averted due to changes in ORS coverage between 2000 and 2017, which is described in detail in appendix 1 (pp 9–10). In the counterfactual analysis, we treated ORS coverage as an independent risk factor and did not take into account how changes in demography or other risk factors affect deaths. We additionally did a sensitivity analysis of these results by halving and doubling the estimated lives that could be saved with ORS treatment (appendix 1 pp 82–83).

**Role of the funding source**

This research was supported by the Bill & Melinda Gates Foundation. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

**Results**

In all years from 2000 to 2017, we found both between-country and within-country variation in the proportion of children younger than 5 years with diarrhoea who received ORT. In general, ORS coverage was highest in south Asia, east Asia, central America, and southern sub-Saharan Africa, and lowest in central sub-Saharan Africa, parts of western and eastern sub-Saharan Africa, the Middle East, and South America (figure I). Within these regions, some countries had fairly uniform subnational distribution of ORS across units, such as Zimbabwe in 2017, where coverage ranged from 35.1% (95% UI 11.8–66.6) in Chivi district, Masvingo province, to 44.6% (16.2–76.7) in Mazowe district, Mashonaland Central province. Other countries had notable subnational variation, such as Peru in 2017, where coverage ranged from 16.1% (12.1–20.6) in Azángaro province, Puno region, to 45.2% (38.2–51.5) in Trujillo province,
Figure 1: Proportion of children younger than 5 years with diarrhoea who received ORT at the second administrative-unit level, 2000 and 2017

Mean proportion of children with diarrhoea who received ORS in 2000 (A) and 2017 (B) or who received RHF in 2000 (C) and 2017 (D). All countries are aggregated to second administrative units. Maps reflect administrative boundaries, land cover, lakes, and population. Dark grey grid cells were classified as barren or sparsely vegetated and had fewer than ten people per 1 km × 1 km grid cell; light grey countries were not included in these analyses. ORS=oral rehydration solution. ORT=oral rehydration therapy. RHF=recommended home fluids.
La Libertad region (figure 1B). In terms of absolute coverage, RHF coverage was lower and more evenly distributed in Peru in 2017, with coverage ranging from 5–0% (2.9–8.5) in Coronel Portillo province, Ucayali, to 19.7% (12.3–28.9) in Daniel Alcides Carrión province, Pasco (figure 1D). Across all LMICs, ORS coverage remained below 50% in 62–6% (12417 of 19823) of units in 2017.

Although most changes were small, we found that ORS coverage increased while RHF coverage decreased between 2000 and 2017 in many locations (figure 1). We found significant increases in ORS coverage nationally and subnationally in Rwanda, Vietnam, Bolivia, Cambodia, and India (figure 1; appendix 1 p 75; appendix 2 pp 1–8, 25–1615), and significant declines in RHF coverage in Rwanda, Burundi, Bolivia, Niger, Chad, and India (figure 1; appendix 1 p 76; appendix 2 pp 9–16, 1616–3206). In Rwanda, ORS coverage increased from 12.0% (95% UI 9.8- to 14.6) to 33.9% (22.9 to 45.4), with an annualised rate of change (AROC) of 10–7% (3.2 to 17.6). At the same time, RHF coverage decreased from 28.1% (16.1 to 41.6) to 10.7% (3.3 to 25.8), with an AROC of −2.8% (−28.3 to 19.7). Increases in ORS, as measured by AROC, were significant (i.e., 95% UIs did not include 0) in 27 of Rwanda’s 30 units, while overall RHT coverage remained constant (appendix 1 pp 75–77; appendix 2 pp 1–8, 3207–4797). Kyrgyzstan, Yemen, and Liberia saw the largest increases in RHF coverage; however, uncertainty around these estimates was high, and only Yemen saw significant increases in RHF use (appendix 1 p 76; appendix 2 pp 9–16). Sudan and South Sudan were the only countries where AROC in ORS coverage declined substantially, with coverage decreasing from 32.3% (26.5 to 38.3) to 19.7% (12.3–28.9), with an AROC of −2.8% (−28.3 to 19.7). Increases in ORS, as measured by AROC, were significant (i.e., 95% UIs did not include 0) in 27 of Rwanda’s 30 units, while overall ORT coverage remained constant (appendix 1 pp 75–77; appendix 2 pp 1–8, 3207–4797). Kyrgyzstan, Yemen, and Liberia saw the largest increases in RHF coverage; however, uncertainty around these estimates was high, and only Yemen saw significant increases in RHF use (appendix 1 pp 75–77; appendix 2 pp 1–8, 3207–4797). Kyrgyzstan, Yemen, and Liberia saw the largest increases in RHF coverage; however, uncertainty around these estimates was high, and only Yemen saw significant increases in RHF use (appendix 1 pp 75–77; appendix 2 pp 1–8, 3207–4797). Kyrgyzstan, Yemen, and Liberia saw the largest increases in RHF coverage; however, uncertainty around these estimates was high, and only Yemen saw significant increases in RHF use (appendix 1 pp 75–77; appendix 2 pp 1–8, 3207–4797). Kyrgyzstan, Yemen, and Liberia saw the largest increases in RHF coverage; however, uncertainty around these estimates was high, and only Yemen saw significant increases in RHF use (appendix 1 pp 75–77; appendix 2 pp 1–8, 3207–4797).

In 2017, the highest number of children with diarrhoea who remained untreated by ORS were in parts of eastern sub-Saharan Africa, north Africa, south Asia, and southeast Asia (figure 2). In 2000, we estimated that approximately 6668000 children (95% UI 5330000–7673000) across the 94 LMICs included in this study were untreated with either ORS or RHF, out of a total of 12873000 children (12344000–13471000) with diarrhoea. Although prevalence of untreated children has declined, a substantial number remain in need of treatment; in 2017, we estimated 6519000 children (95% UI 52540000–7733000) with diarrhoea did not receive either ORS or RHF treatment, out of a total of 13343000 children (12709000–13944000) with diarrhoea, and this burden varied substantially within many countries (figure 2).

In addition to the results presented here, the full array of our model outputs for ORS, RHF, or ORT (either ORS or RHF) is provided in appendix 1 (pp 28–36) and is publicly available online, and can be further explored at various spatial levels via a user-friendly visualisation tool.

We found that inequality in ORS coverage, as measured by the Gini coefficient, decreased in the majority (63 [67%]) of countries from 2000 to 2017. In particular, although there were nine countries (Afghanistan, Cambodia, Cameroon, Côte d’Ivoire, Equatorial Guinea, Guinea, Iraq, Mali, and Mauritania) in 2000 whose Gini coefficient was greater than 0.15, only Afghanistan and Cameroon had coefficients above 0.15 in 2017.

Absolute percentage-point differences between units with the highest and lowest ORS coverage declined in 40 countries, with notable decreases in Equatorial Guinea, Central African Republic, Iraq, Mongolia, Myanmar, and Sierra Leone (figure 3). Absolute inequalities increased in more than half (54 [57%]) of LMICs, with notable increases in Jordan, Colombia, Uzbekistan, Afghanistan, Bolivia, Turkmenistan, Palestine, Benin, and Madagascar (figure 3). By contrast, within-country absolute geographical inequalities in RHF coverage declined in most (55 [59%]) countries, with notable exceptions in Yemen and Tajikistan (appendix 1 p 79).

Analysis of relative deviation from the country mean revealed that 11 LMICs (Afghanistan, Benin, Cameroon, Democratic Republic of the Congo, Colombia, Ethiopia, Guinea, Jordan, Nigeria, Sudan, and Uganda) had at least 50% relative deviation in one of their units in ORS use in 2017 (figure 3). Additionally, as mean national-level ORS coverage increased over time in most (76 [81%]) countries (appendix 1 p 78), within-country relative differences in ORS coverage also declined in 64 (68%) LMICs, with greater than 50% declines in relative deviation in Central African Republic, Equatorial Guinea, Iraq, Mali, Cambodia, Ethiopia, Niger, Senegal, Kyrgyzstan, Togo, Democratic Republic of the Congo, and Côte d’Ivoire (figure 3). Exceptions to this pattern, where relative differences increased more than 20%, included Jordan, Benin, Madagascar, Yemen, Sudan, Suriname, Guatemala, Turkmenistan, and Bolivia. Furthermore, as mean national-level RHF coverage declined over time in most (69 [73%]) countries, within-country relative inequalities in RHF coverage declined in 45 (48%) countries (appendix 1 p 78). In 2017, relative inequalities in RHF coverage remained highest in North Africa and the Middle East (appendix 1 p 78).

We found that mean ORS coverage was less than 50% in 12 of 14 countries where diarrhoeal mortality in 2017 was greater than two children per 1000 (appendix 2 pp 1–8). Furthermore, we found that ORS coverage was negatively correlated with RHF coverage over time in 56–6% (10786 of 19064) of units and was negatively correlated with diarrhoeal mortality over time in 74–7% (14241 of 19064) of units (appendix 1 p 81).
Figure 2: Number of children younger than 5 years with diarrhoea who did not receive ORT at the second administrative-unit level, 2000 and 2017.

Number of children younger than 5 years with diarrhoea who did not receive ORS in 2000 (A) and 2017 (B) or did not receive ORT (either ORS or RHF) in 2000 (C) and 2017 (D). Countries are aggregated to second administrative units. Maps reflect administrative boundaries, land cover, lakes, and population. Dark grey grid cells were classified as barren or sparsely vegetated and had fewer than ten people per 1 km × 1 km grid cell; light grey countries were not included in these analyses. ORS=oral rehydration solution. ORT=oral rehydration therapy. RHF=recommended home fluids.
For ISO 3 codes see https://www.iso.org/obp/ui

To illustrate how our maps can be used to estimate the number of diarrhoeal deaths that were averted by changes in ORS coverage, we did a counterfactual analysis using a previous estimate that 75% ORS coverage could reduce diarrhoeal deaths by 69%.” This estimate is based on a systematic review of three quasi-experimental studies with small sample sizes and that did not adjust for confounding variables (eg, stunting) to examine the risk of death in the absence of ORS treatment; thus, the results of this analysis should be interpreted with some caution. We found that of the 526800 diarrhoeal deaths (95% UI 485300–568900) estimated to have occurred in 2017 in children younger than 5 years across the 94 LMICs included in our analysis, an estimated 299900 deaths (274000–324300) could be attributable to lack of treatment with ORS. We also estimated that increase in ORS coverage during the study period prevented an additional 52230 deaths (36910–68860). Nigeria, India, Ethiopia, Pakistan, Chad, and Madagascar contained units with high numbers of deaths attributable to lack of ORS treatment in 2017; however, these countries also contained units with the highest numbers of deaths averted by improved ORS coverage in 2017 (figure 4). By contrast, an estimated 4850 deaths (2200–10080) globally were due to declines in ORS coverage, with some of the highest numbers of deaths attributable to worsening coverage in units of Sudan, South Sudan, and Pakistan (figure 4). Some of the highest rates of deaths averted were in units of Sierra Leone, where 0·9 deaths (0·2–1·9) were averted per 100 children in Kambia district, Northern Province (figure 4), corresponding to 67 lives (18–141) saved in 2017 in this district alone.

In a sensitivity analysis, we found that, while the geographical patterns in deaths averted remained largely unchanged, the absolute number of averted deaths changed substantially in some places (appendix 1 pp 82–83). Reducing the percentage of diarrhoeal deaths attributable to lack of ORS from 69% to 35% reduced the total number of deaths attributable to lack of ORS...
coverage in 2017 from 299,900 (95% UI 274,000–324,300) to 143,360 (130,400–156,000), the estimated total deaths averted by increase in ORS coverage from 52,230 (36,910–68,860) to 22,760 (15,600–30,650), and the averted deaths in Kambia district, Sierra Leone, from 67 (18–141) to 26 (8–53; appendix 1 p 82).

Figure 4: Averted child diarrhoeal deaths attributable to increased ORS coverage from 2000 to 2017 (A) Number of deaths in children younger than 5 years attributable to lack of ORS treatment in 2017. (B) Number of deaths in children younger than 5 years in 2017 averted by and attributable to changes in ORS coverage between 2000 and 2017. (C) Number of deaths per 1000 children younger than 5 years in 2017 averted by and attributable to changes in ORS between 2000 and 2017. Maps reflect administrative boundaries, land cover, lakes, and population. Dark grey grid cells were classified as barren or sparsely vegetated and had fewer than ten people per 1 km × 1 km grid cell; light grey countries were not included in these analyses. ORS=oral rehydration solution.
Finally, to illustrate how these maps can be used to identify children in need, we present side-by-side maps of diarrhoeal mortality, ORS coverage, and RHF coverage at the unit level for three countries—Colombia, Nigeria, and Sudan—that had subnational locations with higher-than-average mortality rates and lower-than-average ORS coverage (figure 5). In Colombia, ORS and RHF coverage were lowest in the southern Amazonas region, where diarrhoeal burden was highest. In Nigeria, ORS coverage was lowest in the northern region, where diarrhoeal burden was highest. In Sudan, RHF remains widely used to treat diarrhoea, and there was not a clear trend between ORS, RHF, and diarrhoea distributions, but distinct areas in Darfur, in the southeast of the country, had high diarrhoeal mortality and particularly low ORS coverage. To illustrate that this pattern was not present everywhere, we also present results for Peru, where ORS coverage was relatively high in the Amazon Basin rainforests, which is where diarrhoeal mortality was also highest. There were gaps in coverage in the mountainous and arid regions of central and south Peru, where diarrhoeal mortality was lower (figure 5).

Discussion

The discovery that led to the development of ORS as treatment for diarrhoea was hailed as “potentially the most important medical advancement of the century”. More than 50 years later, ORS is recognised as an important treatment for childhood diarrhoea, as well as a crucial component in treating other forms of dehydration, including dehydration-induced kidney injury and Ebola virus disease. By providing high-resolution estimates of the use of different forms of ORT—ORS, RHF, and either ORS or RHF—in children younger than 5 years with diarrhoea in LMICs, this study examines where uptake has occurred and which places stand to gain the most. While we show increases in ORS coverage in many locations, it is striking that these increases have been so incremental, given the importance and simplicity of this intervention. These slow changes are reflected in the relatively low number of total deaths estimated to have been averted by increases in ORS coverage between 2000 and 2017, and the substantial number of children with diarrhoea that remained untreated in 2017. ORS coverage remains below 50% in the majority (62·6%) of second administrative units, and there are various locations with high diarrhoeal mortality rates where geographical inequalities in ORS coverage are high. These areas need to be targeted with improved efforts to increase access to and awareness of this life-saving treatment.

We also show that increases in ORS coverage over time were correlated with declines in RHF coverage in many locations. It is possible that these results represent shifts over time in diarrhoea treatment, which might have contributed to declines in diarrhoeal mortality in these locations; ORS has shown effectiveness in preventing child mortality, whereas the effect of RHF on child mortality is unclear. However, if the rates of decline in RHF exceeded the rates of increase in ORS in some locations, this could have left a proportion of children...
completely untreated and in need of targeted interventions to prevent diarrhoeal mortality. These results further highlight the importance of reaching these vulnerable populations with targeted interventions to improve ORS coverage. It is important to note that there were also locations where there was apparently no relationship between ORS coverage and diarrhoeal mortality over time. This could, in part, be attributed to other risk factors that affect diarrhoeal mortality, which we did not take into account in this analysis.

Our estimates are comparable with previously published estimates at the national level.10,11 We show notable differences in ORS coverage between countries in the same region (eg, Senegal vs Sierra Leone), consistent with a previous review.8 We show that ORS use has increased over time, with greater uptake in some regions compared with others (eg, south Asia vs the Horn of Africa), which is consistent with the conclusions of UNICEF’s 2016 report.12,13 However, we also show that the rates of increase in ORS coverage and decrease in RHF coverage were modest and that uncertainty in these estimates was high, which is consistent with previous studies that showed no substantial increases in RHF coverage between 1990 and 200143 or between 1996 and 2003.44 We also show that relative and absolute geographical inequalities in ORS coverage and decrease in RHF coverage were modest and that uncertainty in these estimates was high, which is consistent with previous studies that showed no substantial increases in RHF coverage between 1990 and 200143 or between 1996 and 2003.44

There are numerous methodological differences between that study and ours; most importantly, the previous study did not separate the effect of ORS from that of RHF. As we show, analysis of ORT (a combined variable) masks spatial and temporal variation in ORS and RHF.

We are surprised to see low use of ORS after so many years of programmes in many countries, especially those with high diarrhoeal burden. Ensuring access to ORS treatment is not only important for treating existing diarrhoea cases, but also in preparing for outbreaks and having supplies ready for emergencies. Moreover, educating caregivers on the causes of diarrhoea mortality—and how ORS can prevent those child deaths—is essential to ensure sustainable uptake. To address shortfalls in coverage, it will be essential to examine the root causes specific to each location. Previous studies have shown that challenges in using ORS include doctor and patient knowledge about ORS; ORS supply, cost, and taste; and access to clean water.14,15 Studies have also shown that improvements in ORS coverage can be driven by changes in government policies, media campaigns, and community culture and beliefs.12,13 According to our results, Sierra Leone had some of the highest ORS coverage in western sub-Saharan Africa in 2017. Sierra Leone has previously been described as an example of how community mobilisation can promote access to and awareness of ORS, even after a devastating civil war.14 Our results also suggest that promotion of RHF over ORS might negatively affect ORS use and that locations with high RHF use, such as Sudan, can have very low ORS coverage. A previous study has similarly shown that inconsistent and unclear diarrhoea treatment recommendations present challenges in Sudan and Somalia and might have had implications for the recent cholera epidemic in Yemen.46 By determining key country-specific drivers of low uptake and subnational inequalities, including various social, cultural, political, and economic factors that might inhibit proper coverage, successful interventions such as those in Sierra Leone could be adapted and applied to similar contexts.

Our study has several limitations. Although we constructed a large database of geolocated ORT coverage data, spatial and temporal gaps remain, and data quality is likely to be variable by source, contributing to uncertainty in our estimates. Thus, results from zones of conflict and political instability, such as Yemen, Syria, Iraq, Afghanistan, and Pakistan, should be interpreted with caution. For RHF modelling, we included a broad range of RHF definitions in the survey data, and the RHF definitions in survey questionnaires do not always correspond to the actual solutions that governments have recommended. In addition, since the denominator of our input data was the proportion of children with diarrhoea (ie, diarrhoea prevalence), sample sizes were very small. Finally, heterogeneity within the data as well as amount of relevant available data varied between countries. Each of these factors probably contributed to uncertainty in our estimates, which varied by indicator and country (appendix 2).

As a further limitation, the modelling framework was optimised for prediction rather than causal inference, and there were overlaps between covariates used to estimate ORS, RHF, and diarrhoeal mortality, so we cannot make any conclusions about causal relationships between them. Additionally, we were unable to incorporate uncertainty into our estimates of the number of children with diarrhoea who were untreated because uncertainty from WorldPop datasets13 was not available. Furthermore, we fit our models using survey data, which depend on recall and are susceptible to biases that could be in the direction of increased or decreased coverage, depending on the context. Lastly, we mapped the reported use of ORS, yet use is not equivalent to proper preparation of the solution.17,46

Future studies should examine the factors that have affected ORS coverage, particularly those that have contributed to shortfalls in efforts to increase coverage, to inform future interventions and implementation studies. Future work should also further investigate coverage of zinc treatment, which has shown effectiveness in reducing undernourishment and diarrhoeal mortality in many countries.47 In addition, promoting zinc use has shown a secondary effect of increasing ORS use in some places,48 thus comprehensive approaches to overcome challenges to uptake and scaling up of coverage are warranted.12 Future work could investigate how missing data affect
estimates of ORS coverage and how to account for this, as well as how to incorporate differences between urban and rural populations into the analysis. In addition, we did not map ORS availability, but rather the prevalence of its use, and future studies could map availability distribution patterns. Future work should examine the co-distribution of different interventions to prevent childhood mortality from diarrhoea, such as the co-distributions of ORS, zinc, and access to clean water. Finally, as with any study that involves estimation, the availability and quality of input data influences the certainty of our estimates; as LMICs work to improve their cause-specific vital registration systems, analyses that incorporate diarrhoea-specific cause of death data in estimates of diarrhoea mortality would improve future updates to this work.

In conclusion, our results show that advancement in ORS coverage was slow from 2000 to 2017, and that within-country inequalities in ORS coverage persist in many LMICs. Depending on the local context, low levels of coverage might reflect challenges in access to ORS or the need for education on the efficacy of ORS in preventing diarrhoea mortality. Increased efforts are needed, particularly where childhood deaths from diarrhoea are high yet ORS coverage remains low; in 2017, 12 of 14 LMICs where diarrhoeal mortality exceeded two children per 1000 had less than 50% ORS coverage. The subnational scale of these mapped estimates can aid in identifying where gaps in coverage of this life-saving intervention remain, contributing to the UN Sustainable Development Goals' commitment to address inequalities and leave no one behind.11 Our results indicate that scaling up of ORS coverage has been insufficient, and that new efforts to improve access are desperately needed.
Department of Physiotherapy and Occupational Therapy (M M Sisay), Nazareth-Slagelse-Ringedt Hospita, Slagelse, Denmark; Department of Ophthalmology (E Skaidarei MD), Hywel Dda University Health Board, Llanelli, UK; Department of Infectious Diseases (A Sokham PhD), Kharkiv National Medical University, Kharkiv, Ukraine; Department of Medicine (R Somayaji), University of Calgary, Calgary, AB, Canada; Hull York Medical School (I N Soyon), University of Hull, Hull City, UK; Division of Community Medicine (C T U Tsang PhD), International Medical University, Kuala Lumpur, Malaysia; Nursing (A Sudarsoy MPH), Muhammadiah University of Sarakarta, Surakarta, Indonesia; Department of Public Health (A Sudarsoyanto), China Medical University, Taiwan; Health Economics (M Sultana), Deakin University, Melbourne, VIC, Australia; Department of Community Health (B F Sunguya PhD), Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; Department of Criminology, Law, and Society (Prof B L Sykes PhD), University of California Irvine, Irvine, CA, USA; Department of Medicine (Prof R Tabarés-Seisdedos PhD), University of Valencia, Valencia, Spain; Carlos III Health Institute (Prof R Tabarés-Seisdedos), Biomedical Research Networking Center for Mental Health Network, Madrid, Spain; Cancer Control Center (T Tabuchi MD), Osaka International Cancer Institute, Osaka, Japan; Anum College of Health Science, Mekele, Ethiopia (D B Tadesse); Research and Development Center for Humanities and Health Management (I U Tarigan PhD), National Institute of Health Research & Development, Jakarta, Indonesia; Department of Public Health and Community Medicine (Prof K R Thankappan MD), Central University of Kerala, Kasaragod, India; Institute of Public Health (R Topor-Madry PhD), Jagiellonian University Medical College, Krakow, Poland; Agency for Health Technology Assessment and Tariff System, Warsaw, Poland (R Topor-Madry); Department of Pathology and Legal Medicine (M R Tovani-Palone PhD), University of São Paulo, Ribeirão Preto, Brazil; Modestum LTD, London, UK (M R Tovani-Palone); Department of Health Economics (B X Tran PhD), Hanoi Medical University, Hanoi, Vietnam; Molecular Medicine and Pathology (K B Tran MD), University of Auckland, Auckland, New Zealand; Clinical Hematology and Toxicology (K B Tran), Maurice Wilkins Centre, Auckland, New Zealand; Department of Microbiology (I Ullah PhD), Iqra National University, Peshawar, Pakistan; TB Culture Laboratory (I Ullah), Mufi Mehmood Memorial Teaching Hospital, Deh Sami, Iran; Sarsfield Hospital, Buenos Aires, Argentina (Prof P Valdez); Department of Medical and Surgical Sciences (Prof F S Violante MD), University of Bologna, Bologna, Italy; Occupational Health Unit (Prof F S Violante), Sant’Orsola Malpighi Hospital, Bologna, Italy; Department of Economics (Prof S Vollmer), University of Göttingen, Göttingen, Germany; Foundation University Medical College (Prof Y Waheed PhD), Foundation University Islamabad, Islamabad, Pakistan; Department of Neurology (Prof Z Younis), Juntendo University, Tokyo, Japan; Department of Preventive Medicine (Prof S Yoon PhD), Korea University, Seoul, South Korea; Department of Health Policy and Management (Prof M Z Younis PhD), Jackson State University, Jackson, MS, USA; School of Medicine (Prof M Z Younis), Tsinghua University, Beijing, China; Department of Health Care Management and Economics (H Yusefzadeh PhD), Urmia University of Medical Science, Urmia, Iran; Department of Medicine (Prof Z Zaidi PhD), University Ferhat Abbas of Setif, Setif, Algeria; Department of Epidemiology and Public Health (N B Zepros), University of Basel, Basel, Switzerland; College of Medicine and Health Sciences (T A Zerfu), Dilla University, Dilla, Ethiopia; School of Public Health (Y Zhang PhD), Hubei Province Key Laboratory of Occupational Hazard Identification and Control (Y Zhang), Wuhan University of Science and Technology, Wuhan, China; School of Biologics and Pharmaceutical Engineering (X G Zhao), Wuhan Polytechnic University, Wuhan, China; Health Technology Assessment Unit (Y H Zuniga BS), Department of Health Philippines, Manila, Philippines; #MentalHealthPH, Quezon City, Philippines (Y H Zuniga).

Contributors
P A Lindstedt, M M Baumann, and K E Wiens collected, cleaned, and vetted the data. K E Wiens produced estimates and K E Wiens, R C Reiner Jr, and A Deshpande vetted the models and the results. K E Wiens prepared the first draft of the manuscript. K E Wiens, K B Johnson, M M Baumann, and P A Lindstedt constructed the figures and tables. R C Reiner Jr and S I Hay provided overall direction and guidance. B F Blacker, K E Wiens, and R C Reiner Jr managed the project. K E Wiens, I E Schaeffer, M M Baumann, P A Lindstedt, and B F Blacker finalised the manuscript on the basis of comments from other authors and reviewer feedback. P A Lindstedt managed appendix I. M M Baumann and C A Welgan created appendix 2. All other authors provided data or developed models for indicators, reviewed results, initiated modelling infrastructure, or reviewed and contributed to the Article; their contributions can be found in appendix 1 (pp 158–162).

Declaration of interests
M L Bell reports grants from US Environmental Protection Agency, National Institute of Health (NIH), and the Wellcome Trust Foundation, during the conduct of the study; and honoraria or travel reimbursement from NIH (for review of grant proposals), American Journal of Public Health (participation as editor), Global Research Laboratory and Seoul National University, Royal Society (London, UK), Ohio University, Atmospheric Chemistry Gordon Research Conference, Johns Hopkins, Bloomberg School of Public Health, Arizona State University, Ministry of the Environment, Japan, Hong Kong Polytechnic University, University of Illinois—Champaign, and University of Tennessee—Knoxville, outside of the submitted work. A Deshpande reports grants from Bill & Melinda Gates Foundation, during the conduct of the study. S M S Islam reports grants from National Heart Foundation of Australia, Institute for Physical Activity and Nutrition, and Deakin University, during the conduct of the study. V Jha reports grants from Baxter Healthcare, GlaxoSmithKline, NephroPlus, and Zydus Cadila, and personal fees from AstroZeneca, outside of the submitted work. J J Jozwiak reports personal fees from Amgen, ALAB Laboratoria, Teva, Synexus, and Boehringer Ingelheim, outside of the submitted work. W Mendoza is a Program Analyst in Population and Development at the UN Population Fund Country Office in Peru, an institution which does not necessarily endorse this study. M J Postma holds stocks in Ingress Health and Pharmacoconomics Advice Groningen and is advisor to Asc Academics, all pharmacoconomics consultancy companies. M J Postma reports grants and personal fees from Merck Sharpe & Dohrme, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, Novavax, Bristol-Myer Squibb, AstaZeneca, Sanofi, IQVIA, Seqirus, Quintiles, Nocartis, and Pharmacoeconomics Advice, grants from Bayer, BioMerieux, WHO, EU, FIND, Antilope, DIKTI, LPDP, and Budi; and other support from Ingress Health, Pharmacoconomics Advice Groningen, and Asc Academics, outside of the submitted work. J A Singh reports personal fees from CzeHa/Horizontal, Medisys, Fidia, UBM, Trio health, Mediscape, WebMD, Clinical Care options, Clearview
Healthcare Partners, Putnam Associates, Spherix, Practice Point Communications, NIH, American College of Rheumatology, and Simply Speaking; other support from AstraZeneca Pharmaceuticals and Viking Pharmaceuticals; non-financial support from US Food and Drug Administration Aduritis Advisory Committee. Steering committee of OMERACT (an international organisation that develops measures for clinical trials and receives arms-length funding from 12 pharmaceutical companies), Veterans Affairs Rheumatology Field Advisory Committee, outside of the submitted work. J A Singh is editor and director of the University of Alabama at Birmingham Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. All other authors declare no competing interests.

Data sharing
The source code used to generate estimates is available online. The study data, including full sets of estimates at the first and second administrative levels, are available online.

Acknowledgments
This work was primarily supported by a grant from the Bill & Melinda Gates Foundation (OPP1132415). L Gueru has received support from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Finance Code 001), Conselho Nacional de Desenvolvimento Científico e Tecnológico and Fundação de Amparo à Pesquisa do Estado de Minas Gerais. O O Adetokunboh acknowledges the South African Department of Science and Innovation and the National Foundation Research. S M Aljunid acknowledges the Department of Health Policy and Management, Faculty of Public Health, Kuwait University and International Centre for Casemix and Clinical Coding, Faculty of Medicine, University of National of Malaysia for the approval and support to participate in this research project. H T Atalay acknowledges Aksum University. M Aulasoa and C Hertelui are partially supported by a grant of the Romanian National Authority for Scientific Research and Innovation, CNCS-UEFISCEDI, project number PN-II-P4-ID-PCCF-2016-0084. P S Azizparchi was supported by an Australian National Health and Medical Research Council (NHMRC) early career fellowship. A Badawi is supported by the Public Health Agency of Canada. T W Bärnighausen was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the German Federal Ministry of Education and Research; the EU; the Wellcome Trust; and from National Institute of Child Health and Human Development of National Institutes of Health (NIH; R01HD084233). National Institute on Aging of NIH (P01-AG04710), National Institute of Allergy and Infectious Diseases of NIH (R01-AI124389 and R01-AI112339), as well as for Fogarty International Center of NIH (DA-37-TW009773). G B Britton is supported by the Generalitat de Catalunya (2017 SGR 957, 2017SGR1163). G C Patton is funded by an NHMRC Fellowship. A M Samy received a fellowship from the Egyptian Fullbright Mission programme. M M Santric-Milicevic acknowledges the support of the Ministry of Education, Science and Technological Development of the Republic of Serbia (contract number 175087). A Sheikh acknowledges the support of Health Data Research UK. M R Sobhiyeh acknowledges the Clínic Medical Research Development Center of Imam Reza Hospital, Kermanshah University of Medical Sciences for their wise advice. R Tabarés-Seisdedos was supported in part by grant PI17/00719 from Instituto de Salud Carlos III—FEDER. B Umukhran acknowledges Manipal Academy of Higher Education, Manipal. R W Weaver was supported by the Bill & Melinda Gates Foundation grant OPP1127433. C Wuytsonge was supported by the South African Medical Research Council.

Editorial note: the Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations.

References
1. Das JK, Salam RA, Bhutta ZA. Global burden of childhood diarrhea and interventions. Curr Opin Infect Dis 2014; 27: 451–58.
2. Das JK, Lassi ZS, Salam RA, Bhutta ZA. Effect of community based interventions on childhood diarrhea and pneumonia: uptake of treatment modalities and impact on mortality. BMC Public Health 2013; 13: S29.
3. Nalin DR, Cash RA, Islam R, Molla M, Phillips RA. Oral maintenance therapy for cholera in adults. Lancet 1968; 292: 370–72.
4. Pearce NF, Sack BR, Mitra RC, et al. Replacement of water and electrolyte losses in cholera by an oral glucose-electrolyte solution. Ann Intern Med 1969; 70: 1173.
5. Mahalanabis D, Choudhuri AB, Bagchi NG, Bhattacharya AK, Simpson TW. Oral fluid therapy of cholera among Bangladeshi refugees, 1973. Bull World Health Organ 2001; 79: 471–79.
6. Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1713–88.
7. Victoria CG, Bryce J, Fontaine O, Monasch R. Reducing deaths from diarrhoea through oral rehydration therapy. Bull World Health Organ 2000; 78: 1246–55.
8. Glass RJ, Stoll BJ. Oral rehydration therapy for diarrheal diseases: a 50-year perspective. JAMA 2018; 320: 865–73.
9. Binder HJ, Brown I, Ramakrishna BS, Young GP. Oral rehydration therapy in the second decade of the twenty-first century. Curr Gastroenterol Rep 2014; 16: 376.
10. UNICEF. One is too many: ending child deaths from pneumonia and diarrhoea. New York, NY: UNICEF, 2016.
11. Wilson SE, Morris SS, Gilbert SS, et al. Scaling up access to oral rehydration therapy: a window of opportunity. Lancet 2013; 381: 810–44.
12. Wagner Z, Asimwe JB, Dow WH, Levine D. The role of price and convenience in use of oral rehydration salts to treat child diarrhoea: a cluster randomized trial in Uganda. PLoS Medicine 2019; 16(4): e1002734.
13. National Primary Health Care Development Agency, Federal Ministry of Health. Essential childhood medicines scale-up plan, 2012–2015. Abuja: Federal Republic of Nigeria, 2012.
14. Munyes MK, Walker CLF, Black RE. The effect of oral rehydration solution and recommended home fluids on diarrhoea mortality. Int J Epidemiol 2019; 39: 75–87.
Articles

15. Skaftun EK, Ali M, Norheim OF. Understanding inequalities in child health in Ethiopia: health achievements are improving in the period 2000–2011. PLoS One 2014; 9: e906460.

16. Li Z, Li M, Subramanian SV, Lu C. Assessing levels and trends of child health inequality in 88 developing countries: from 2000 to 2014. Glob Health Action 2017; 10: 168385.

17. Unger CC, Salam SA, Sarker MA, Black R, Cravioto A, Azifeen SE. Treating diarrhoeal disease in children under five: the global picture. Arch Dis Child 2014; 99: 273–78.

18. Zwijers G, Simpson E, Moodley M. Treatment of diarrhoea in young children: results from surveys on the perception and use of oral rehydration solutions, antibiotics, and other therapies in India and Kenya. J Glob Health 2013; 3: 010403.

19. Reyes H, Guiscafré H, Sarti E, Montoya Y, Tapia R, Gutiérrez G. Urban-rural variations in medical care of children with diarrhea in Mexico. Salud Publica Mex 1996; 38: 157–66.

20. Reiner RC Jr, Graetz N, Casey DC, et al. Variation in childhood diarrheal morbidity and mortality in Africa, 2000–2015. N Engl J Med 2018; 379: 1128–38.

21. Kinyoki DK, Osogood-Zimmerman AE, Pickering BV, et al. Mapping child growth failure across low- and middle-income countries. Nature 2020; 577: 231–34.

22. Burstein R, Henry NJ, Collison ML, et al. Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature 2019; 569: 53–58.

23. Lam F, Pro G, Agraval S, et al. Effect of enhanced detailing and mass media on community use of oral rehydration salts and zinc during a scale-up program in Gujarat and Uttar Pradesh. J Glob Health 2019; 9: 010501.

24. Lam F, Abdulwahab A, Houdek J, et al. Program evaluation of an ORS and zinc scale-up program in 8 Nigerian states. J Glob Health 2019; 9: 010502.

25. Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2017 (GBD 2017) Socio-demographic Index (SDI) 1950–2017. March 30, 2019. http://ghdx.healthdata.org/record/ihme-database-gbd-1950-2017-socio-demographic-index-sdi-1950%2F2017 (accessed June 1, 2019).

26. Stevens GA, Alkema L, Black RE, et al. Guidelines for accurate and transparent health estimates reporting: the GATHER statement. Int J Epidemiol 2016; 45: i63–69.

27. Greenland K, Chipungu J, Chilengi R, Curtis V. Theory-based formative research on oral rehydration salts and zinc use in Lusaka, Zambia. BMC Public Health 2016; 16: 312.

28. Walker CLF, Black RE. Zinc for the treatment of diarrhoea: effect on diarrhoeal morbidity, mortality and incidence of future episodes. Int J Epidemiol 2010; 39 (suppl 1): 63–69.

29. Gebremedhin S, Marno G, Gezahign H, Kung’u J, Adish A. The effectiveness bundling of zinc with Oral Rehydration Salts (ORS) for improving adherence to acute watery diarrhea treatment in Ethiopia: cluster randomised controlled trial. BMC Public Health 2016; 16: 457.

30. Kung’u JK, Otwaloni O, Essien G, Aminu FT, Ngpi-Teta I, Neufeld LM. Promotion of zinc tablets with ORS through child health interventions in Nigeria. J Health Popul Nutr 2015; 33: 9–19.

31. Schroeder K, Battu A, Wentworth L, et al. Increasing coverage of paediatric diarrhoea treatment in high-burden countries. J Glob Health 2019; 9: 0010503.

32. UN Committee for Development Policy. Leaving no one behind: summary from UN Committee for Development Policy. 2018. https://sustainabledevelopment.un.org/content/documents/2764711_july_PM_2_Leaving_no_one_behind_Summary_from_UN_Committee_for_Development_Policy.pdf (accessed June 7, 2019).